Antiangiogenic drugs in ovarian cancer.
BACKGROUND
There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer.


OBJECTIVE
The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer.


CONCLUSIONS
Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.
Markman
Maurie
M
The University of Texas MD Anderson Cancer Center, Department of Gynecologic Medical Oncology, Houston, Texas 77005, USA. mmarkman@mdanderson.org
D000230:Adenocarcinoma / Q000098:blood supply* / Q000473:pathology; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000473:pathology
D020533:Angiogenesis Inhibitors